C124H225N61O28S2 · 3082.6 g/mol · PubChem CID 176453931 ↗
PTD-DBM
also known as Protein Transduction Domain-Dishevelled Binding Motif, PTD-fused Dvl-binding motif
Fusion peptide combining a protein transduction domain with a Dishevelled-binding motif. Inhibits CXXC5–Dishevelled interaction, activating Wnt/β-catenin signaling. Animal models demonstrate hair regeneration via PGD2-mediated pathway reversal and accelerated wound healing with reduced scar formation. [lee-2015][ryu-2023][lee-2023]
- Class
- Fusion Peptide
- Evidence level
- Strong animal evidence
- Regulatory status
- Not FDA-approved (US) — research use only
At a glance
Topical / SQ · Study-dependent
Primary target — CXXC5–Dishevelled protein-protein interaction.
Pathway — Inhibit CXXC5 binding to Dishevelled → Release Wnt/β-catenin pathway inhibition [lee-2015][ryu-2023].
Downstream effect — Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation.
Origin — Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5.
Feedback intact — Not applicable — pathway derepression rather than receptor agonism.
| Parameter | Value |
|---|---|
| Wound healing protocol | Hydrogel patch delivery (concentration not disclosed)Pyrogallol-HA patch, murine model. |
| Hair regeneration protocol | Topical application (exact dose not disclosed)Wound-induced hair neogenesis model, mice. |
| Evidence basis | Animal models only (mice) |
| Co-administration | Valproic acid (GSK-3β inhibitor) for wound healing synergy [lee-2023]Combined treatment maximized scar reduction. |
| Human translation | No published human studies |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
- — Active malignancy (Wnt pathway involvement in tumorigenesis)
- — Pregnancy / lactation (no safety data)
- — History of Wnt-driven tumors
- — Skin lesions with uncertain malignant potential
- 01Wound Healing Protocol (Animal Model)
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days. [lee-2023]
- 02Hair Regeneration Protocol (Animal Model)
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models. [ryu-2023]
- 03Combination Therapy
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream. [lee-2023]
- 04Storage & Handling
Not disclosed in available literature. Peptide stability and storage conditions not published.
Frequently asked
Is PTD-DBM FDA-approved?
PTD-DBM is not FDA-approved in the United States and is handled as a research compound (research use only). Regulatory status may differ in other jurisdictions.
Sources
of 40 rendered claims carry a resolvable citation.
- [lee-2015]Lee 2015 — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
Cell Metab, 2015
Discovery paper for MOTS-c. Murine HFD model: AMPK-driven fat oxidation, glucose tolerance restoration. - [lee-2023]Lee 2023 — Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.
journal, 2023 - [ryu-2023]Ryu 2023 — CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2).
journal, 2023